NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Combined Estrogen–Progestogen Contraceptives and Combined Estrogen–Progestogen Menopausal Therapy. Lyon (FR): International Agency for Research on Cancer; 2007. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 91.)
Combined Estrogen–Progestogen Contraceptives and Combined Estrogen–Progestogen Menopausal Therapy.
Show detailsWorking Group Members1
Garnet L. Anderson, Women's Health Initiative, Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, M3-A410, PO Box 19024, Seattle, WA 98109, USA
Philippe Autier, Unit of Epidemiology, Prevention and Screening, Jules Bordet Institute, Boulevard de Waterloo 125, Brussels 1000, Belgium
Valerie Beral, Cancer Epidemiology Unit, University of Oxford, Richard Doll Building, Roosevelt Drive, Headington, Oxford OX3 7LF, United Kingdom (Subgroup Chair, Cancer in Humans)
Maarten C. Bosland, Department of Environmental Medicine, New York University School of Medicine, 57 Old Forge Road, Tuxedo, NY 10987, USA (Subgroup Chair, Other Relevant Data)
Esteve Fernández, Cancer Prevention & Control Unit, Catalan Institute of Oncology, Avenue Gran Via s/n Km. 2.7, 08907 L'Hospitalet (Barcelona), Spain
Sandra Z. Haslam, Breast Cancer & the Environment Research Center, Department of Physiology, Michigan State University, 2201 Biomedical and Physical Sciences Building, East Lansing, MI 48824, USA
David G. Kaufman2, Department Pathology & Laboratory Medicine, University of North Carolina at Chapel Hill, 620 Brinkhous-Bullitt Building, CB 7525, Chapel Hill, NC 27599-7525, USA
Carlo La Vecchia, Laboratory of General Epidemiology, Mario Negri Institute, via Eritrea 62, 20157 Milan, Italy (Overall Chair)
Alfredo A. Molinolo, Oral & Pharyngeal Cancer Branch, National Institute of Dental & Craniofacial Research, Building 30, Room 213, 30 Convent Drive, Bethesda, MD 20892-4340, USA (Subgroup Chair, Cancer in Experimental Animals)
Polly A. Newcomb (not present for evaluations), Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle WA 98109, USA (Subgroup Chair, Exposure Data)
Fritz F. Parl, Department of Pathology, The Vanderbilt Clinic TVC 4918, Vanderbilt University Medical Center, 23rd Avenue South at Pierce Street, Nashville, TN 37232-5310, USA
Julian Peto, Department of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom
Giuseppe Rosano3 (not present for evaluations), Cardiovascular Research Unit, Department of Medical Sciences, San Raffaele-Tosinvest Sanita, Via Suvereto 10, 00139 Roma (RM) – Lazio, Italy
Deodutta Roy, Department of Environmental & Occupational Health, Robert Stempel School of Public Health, Florida International University, Building HLS 2, Room 591, 11200 SW 8th Street, Miami, FL 33199, USA
Frank Z. Stanczyk (unable to attend), Reproductive Endocrine Research Laboratory, Women's & Children's Hospital, Keck School of Medicine, University of Southern California, 1240 N. Mission Road, Room 1M2, Los Angeles, CA 90033, USA
David B. Thomas, Program in Epidemiology, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA
Lars Vatten, Department of Community Medicine & General Practice, Norwegian University of Science & Technology, Eirik Jarls Gate 10, 6th floor, 7489 Trondheim, Norway
Invited Specialists
Ted Junghans, Technical Resources International Inc, 6500 Rock Spring Drive, Suite 650, Bethesda, MD 20817-1197, USA
Steve Olin, ILSI Risk Science Institute, One Thomas Circle, NW, 9th Floor, Washington, DC 20005-5802, USA
Samuel Shapiro4, Department of Public Health, University of Cape Town Medical School, Anzio Road, Observatory, South Africa
Randall S. Stafford5, School of Population Health, University of Auckland, Private Bag 92019, Auckland 1020, New Zealand
Representative
Charles William Jameson, Report on Carcinogens, National Institute of Environmental Health Sciences, PO Box 12233, 79, Alexander Drive, Research Triangle Park, NC 27709, USA
Observer
Observer for the European Federation of Pharmaceutical Industries and Associations (EFPIA)
Jens U. Meyer6, Global Medical Development, Gynecology & Andrology, Central Medical Affairs, Schering AG, Müllerstrasse 178, 13342 Berlin, Germany
IARC Secretariat
Robert Baan, IARC Monographs programme (Rapporteur, Subgroup on Other Relevant Data)
Julien Berthiller, Gene–Environment Epidemiology
Vincent James Cogliano, IARC Monographs programme (Head of Programme)
Carolyn Dresler, Tobacco and Cancer
Fatiha El Ghissassi, IARC Monographs programme (Co-Rapporteur; Subgroup on Other Relevant Data)
Silvia Franceschi, Infections and Cancer Epidemiology
Maria-Alice G. Gonçalves, Gene–Environment Epidemiology
Yann Grosse, IARC Monographs programme (Responsible Officer; Rapporteur; Subgroup on Cancer in Experimental Animals)
Neela Guha, Gene–Environment Epidemiology
Manuela Marron, Gene–Environment Epidemiology
Jane Mitchell, IARC Monographs programme (Editor)
Nikolai Napalkov, IARC Monographs programme
Béatrice Secretan, IARC Monographs programme (Rapporteur, Subgroup on Exposure Data)
Kurt Straif, IARC Monographs programme (Rapporteur; Subgroup on Cancer in Humans)
Andreas Ullrich, Programme in Cancer Control, Department of Chronic Diseases and Health Promotion (CHP), World Health Organization, 20, Avenue Appia, 1211 Geneva 27, Switzerland
Administrative assistance
Sandrine Egraz
Brigitte Kajo
Martine Lézère
Helene Lorenzen-Augros
Footnotes
- 1
Working Group Members and Invited Specialists serve in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only.
- 2
Received past research support from Organon (a unit of Akzo-Nobel). There are no discussions or expectations of future research support.
- 3
Receives a minor amount of travel support for talks sponsored by Solvay S.A. and Pfizer Inc.
- 4
Serves as a scientific consultant to Schering AG. Also received a minor amount of travel support to talk at a meeting sponsored by Organon (a unit of Akzo Nobel).
- 5
Received research support from Glaxo Smith Kline and is in discussions with them about future research support.
- 6
Employed by Schering AG
- LIST OF PARTICIPANTS - Combined Estrogen–Progestogen Contraceptives and Combined...LIST OF PARTICIPANTS - Combined Estrogen–Progestogen Contraceptives and Combined Estrogen–Progestogen Menopausal Therapy
Your browsing activity is empty.
Activity recording is turned off.
See more...